Cell Signaling & Oncology
The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].
Cell Signaling and Oncology products Library
For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
 Axon 5051 - Cell signaling and Oncology Library.xls |
|
[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 1989 | (+)-JQ1 |
Potent and selective BET bromodomain inhibitor |
€60.00 | |
| 3822 | (+)-JQ1 carboxylic acid | (+)-JQ1 derivative; PROTAC precursor | €110.00 | |
| 3873 | (-)-JQ-1 | Inactive enantiomer of (+)-JQ1 | €120.00 | |
| 3696 | ABBV-075 | Highly potent and orally bioavailable BET bromodomain (BRD) inhibitor | €110.00 | |
| 3956 | ABBV-744 | First-in-class highly BDII (Bromodomain II)-selective BET bromodomain inhibitor | Inquire | |
| 3039 | ACY-241 | Selective and orally available HDAC6 inhibitor | €120.00 | |
| 2269 | AK 1 | Potent inhibitor of SIRT with good selectivity for SIRT2 over SIRT1 and SIRT3 | €90.00 | |
| 2270 | AK 7 | Potent, brain-permeable and selective inhibitor of SIRT2 | €90.00 | |
| 1490 | Anacardic acid A | HAT inhibitor | €60.00 | |
| 2394 | AR-42 | HDAC inhibitor | €125.00 | |
| 3944 | ARV-825 | Potent and selective protein BRD4 degrader | Inquire | |
| 5052 | Axon Ligands™ Epigenetic compound library | Axon Ligands™ Epigenetic compound library | Inquire | |
| 3833 | AZD5153 HNT salt | Potent, selective, and orally available BET/BRD4 bromodomain inhibitor | Inquire | |
| 2635 | BAY-598 | Selective inhibitor of SMYD2 | €110.00 | |
| 2735 | BCI-121 | Inhibitor of SMYD3 | €90.00 | |
| 3115 | Belinostat | HDAC inhibitor | €70.00 | |
| 3397 | BG45 | HDAC inhibitor (1, 2, 3 Selective) | €80.00 | |
| 3037 | BI-894999 | Potent, selective and orally active BET inhibitor | €165.00 | |
| 1692 | BIX 01294 trihydrochloride | HMTase inhibitor (G9a and G9a-like protein) | €80.00 | |
| 2306 | Bizine | Potent LSD1 inhibitor with selectivity over MAO-A/B, and LSD2 | €120.00 | |
| 3399 | BML-210 | HDAC inhibitor | €80.00 | |
| 3716 | BMS-986158 | BET bromodomain (BRD) inhibitor | Inquire | |
| 2471 | BRD 73954 | Dual HDAC 6/8 inhibitor with excellent selectivity over the other HDACs | €85.00 | |
| 1781 | C 646 | HAT inhibitor (p300/CBP selective) | €60.00 | |
| 2803 | Cambinol | Inhibitor of SIRT1 and SIRT2 | €95.00 | |
| 2776 | CD161 | Potent, selective, and orally active BET bromodomain inhibitor | €135.00 | |
| 3764 | CFT-8634 | Selective orally bioavailable BRD9 degrader | Inquire | |
| 2250 | CHR 6494 trifluoroacetate | Specific, first-in-class inhibitor of histone kinase Haspin | €120.00 | |
| 2014 | CI 994 | HDAC inhibitor that causes histone hyperacetylation in living cells | €70.00 | |
| 2812 | CM-272 | First-in-class potent, selective and reversible inhibitor of G9a/DNMT | €130.00 | |